Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;26(10):1751-1761.
doi: 10.1038/s41593-023-01436-y. Epub 2023 Sep 14.

GluN2A mediates ketamine-induced rapid antidepressant-like responses

Affiliations

GluN2A mediates ketamine-induced rapid antidepressant-like responses

Tonghui Su et al. Nat Neurosci. 2023 Oct.

Abstract

Ketamine was thought to induce rapid antidepressant responses by inhibiting GluN2B-containing N-methyl-D-aspartic acid (NMDA) receptors (NMDARs), which presents a promising opportunity to develop better antidepressants. However, adverse side effects limit the broader application of ketamine and GluN2B inhibitors are yet to be approved for clinical use. It is unclear whether ketamine acts solely through GluN2B-dependent mechanisms. The present study reports that the loss of another major NMDAR subunit, GluN2A, in adult mouse brains elicits robust antidepressant-like responses with limited impact on the behaviors that mimic the psychomimetic effects of ketamine. The antidepressant-like behavioral effects of broad NMDAR channel blockers, such as ketamine and MK-801 (dizocilpine), were mediated by the suppression of GluN2A, but not by the inhibition of GluN2B. Moreover, treatment with ketamine or MK-801 rapidly increased the intrinsic excitability of hippocampal principal neurons through GluN2A, but not GluN2B. Together, these findings indicate that GluN2A mediates ketamine-triggered rapid antidepressant-like responses.

PubMed Disclaimer

References

    1. Nierenberg, A. A. et al. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 157, 1423–1428 (2000). - PubMed - DOI
    1. Al-Harbi, K. S. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence 6, 369–388 (2012). - PubMed - PMC - DOI
    1. Duman, R. S. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res https://doi.org/10.12688/f1000research.14344.1 (2018).
    1. Gibbons, R. D. et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am. J. Psychiatry 164, 1356–1363 (2007). - PubMed - DOI
    1. Kim, J., Farchione, T., Potter, A., Chen, Q. & Temple, R. Esketamine for treatment-resistant depression−first FDA-approved antidepressant in a new class. N. Engl. J. Med. 381, 1–4 (2019). - PubMed - DOI

Publication types

LinkOut - more resources